Clinical clearing of psoriasis by 6-thioguanine correlates with cutaneous T-cell depletion via apoptosis: Evidence for selective effects on activated T lymphocytes

Archives of Dermatology

Volumn 135, Issue 12, 1999, Pages 1495-1502

  Murphy, Frank P ^a   Coven, Todd R ^a   Burack, Lauren H ^a   Gilleaudeau, Patricia ^a   Cardinale, Irma ^a   Auerbach, Robert ^a   Krueger, James G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TIOGUANINE;

ALOPECIA; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; LYMPHOCYTE DEPLETION; MALE; PRIORITY JOURNAL; PSORIASIS; T LYMPHOCYTE; THROMBOCYTOPENIA;

ADMINISTRATION, TOPICAL; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL DIVISION; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; HUMANS; KERATINOCYTES; LYMPHOCYTE ACTIVATION; MALE; PSORIASIS; T-LYMPHOCYTES; THIOGUANINE;

EID: 0032787131     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Gubner R. Effect of "aminopterin" on epithelial tissues. Arch Dermotol Syphilol. 1951;64:688-699.
2. Rees RB, Bennett JH. Methotrexate vs aminopterin for psoriasis. Arch Dermatol. 1961;83:970-972.
3. Van Scott EJ, Reinertson RP. Morphologic and physiologic effects of chemotherapeutic agents in psoriasis. J Invest Dermatol. 1959;33:357-364.
4. Kravetz RE, Balsam T. Treatment of psoriasis with mercaptopurine. Arch Dermatol. 1961;84:597-602.
5. Demis DJ, Brown CS, Crosby WH. Thioguanine in the treatment of certain autoimmune, immunologic and related diseases. Am J Med. 1964;37:195-205.
6. Waksman BH. Auto-immunization and the lesions of auto-immunity. Medicine 1962;41:93-94.
7. Gottlieb AB, Krueger JG. The role of activated T-lymphocytes. In: Dubertret L. ed. Psoriasis. Brescia, Italy: ISED Publishing Co: 1994:63-71.
8. Gottlieb AB, Lifshitz B, Fu SM, Staiano-Coico L, Wang CY, Carter DM. Expression of HLA-DR molecules by keratinocytes and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J Exp Med. 1986;164:1013-1028.
9. Gottlieb AB. Immunologic mechanisms in psoriasis. J Am Acad Dermatol. 1988; 18:1376-1380.
10. Grossman RM, Krueger J, Yourish D, et al. Interleukin-6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A. 1989;86:6367-6371.
11. Krueger JG, Krane JF, Carter DM, Gottlieb AB. Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. J Invest Dermatol. 1990; 94(suppl):135S-140S.
12. Gottlieb AB. Immunologic mechanisms in psoriasis. J Invest Dermatol. 1990; 95:18S-19S.
13. Gottlieb AB, Krueger JG, Khandke L, Grossman RM, Krane J, Carter DM. Role of T-cell activation in the pathogenesis of psoriasis. Ann N Y Acad Sci. 1991;636: 377-379.
14. Gottlieb AB, Grossman RM, Khandke L, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992;98:302-309.
15. Ellis CN, Gorsulowsky DC, Hamilton TA, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA. 1986;256:3110-3116.
16. Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial. N Engl J Med. 1991;324:277-284.
17. Fry L. The role of the T cell in psoriasis and the action of cyclosporin in this disease. Acta Derm Venereol (Stockh). 1989;146:133-135.
18. van Joost Th, Bos JD, Heule F, Meinarder MMHM. Low-dose cyclosporin A in severe psoriasis: a double-blind study. Br J Dermatol. 1988;118:183-190.
19. Jeffes WM III, McCullough JL, Pittelkow MR, et al. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol. 1995; 104:183-188.
20. Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995;1:442-447.
21. Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis. J Am Acad Dermatol. 1987;17:962-971.
22. Gomez EC, Menendez L, Frost P. Efficacy of mycophenolic acid for the treatment of psoriasis. J Am Acad Dermatol. 1979;1:531-537.
23. Jones EL, Epinette WW, Hackney VC, Menendez L, Frost P. Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol. 1975;65:537-542.
24. Spatz S, Rudnicka A, McDonald CJ. Mycophenolic acid in psoriasis. Br J Dermatol. 1978;98:429-435.
25. Marinari R, Fleischmajer R, Schragger AH, Rosenthal AL. Mycophenolic acid in the treatment of psoriasis: long-term administration. Arch Dermatol. 1977;113: 930-932.
26. Lynch WS, Roenigk HH Jr. Mycophenolic acid for psoriasis. Arch Dermatol. 1977; 113:1203-1208.
27. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest. 1996;98:1878-1887.
28. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med. 1995;332: 581-568.
29. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). N Engl J Med. 1997;336:1041-1045.
30. Armitage JO, Burns CP. Maintenance of remission in adult acute nonmyeloblastic leukemia using intermittent courses of cytosine arabinoside (NSC-752). Cancer Treat Rep. 1976;60:585-589.
31. Lewis JP, Unman JW, Marshall GJ, Patak TF, Bateman JR. Randomized clinical trial of cytosine arabinoside and 6-thioguanine in remission induction and consolidation of adult nonlymphocytic acute leukemia. Cancer. 1977;39:1387-1396.
32. Valeriote F, Vietti T, Edelstein M. Combined effect of cytosine arabinoside and thiopurines. Cancer Treat Rep. 1976;60:1925-1934.
33. Spiers AS, Kaur J, Galton DAG, Goldman JM. Thioguanine as primary treatment for chronic granulocytic leukemia. Lancet. 1975;1:829-833.
34. Molin L, Thomsen K. Thioguanine treatment in psoriasis. Acta Derm Venereol (Stockh). 1987;67:85-88.
35. Zackheim HS, Glogau RG, Fisher DA, Maibach HI. 6-Thioguanine treatment of psoriasis: experience in 81 patients. J Am Acad Dermatol. 1994;30:452-458.
36. Vallat VP, Gilleaudeau P, Battat L, et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med. 1994;180:283-296.
37. Khandke L, Ashinoff R, Krane JF, et al. Cyclosporine in psoriasis treatment: inhibition of keratinocyte cell-cycle progression in G1 independent of effects on transforming growth factor-alpha/epidermal growth factor receptor pathways. Arch Dermatol. 1991;127:1172-1179.
38. Darzynkiewicz Z, Bruno S, Del Bino G, et al. Features of apoptotic cells measured by flow cytometry. Cytometry. 1992;13:795-808.
39. Kao NL, Rosenblate HJ. 6-Thioguanine therapy for psoriasis causing toxic hepatic venoocclusive disease. J Am Acad Dermatol. 1993;28:1017-1018.
40. Gill RA, Onstad GR, Cardamone JM, Maneval DC, Sumner HW. Hepatic venoocclusive disease caused by 6-thioguanine. Ann Intern Med. 1982;96:58-60.
41. Satti MB, Weinbren K, Gordon-Smith EC. 6-Thioguanine as a cause of toxic venoocclusive disease of the liver. J Clin Pathol. 1982;35:1086-1091.
42. Krivoy N, Raz R, Carter A, Alroy G. Reversible hepatic veno-occlusive disease and 6-thioguanine [letter]. Ann Intern Med. 1982;96:788.
43. Griner PF, Elbadawi A, Packman CH. Veno-occlusive disease of the liver after chemotherapy of acute leukemia: report of two cases. Ann Intern Med. 1976;85: 578-582.
44. Krueger JG, Wolfe JT, Nabeya RT, et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med. 1995;182:2057-2068.
45. Johnson R, Staiano-Coico L, Austin L, Cardinale I, Nabeya-Tsukifuji R, Krueger JG. PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in normal and malignant T-lymphocytes. Photochem Photobiol. 1996;63: 566-571.
46. Brox LW, Birkett L, Belch A. Clinical pharmacology of oral thioguanine in acute myelogenous leukemia. Cancer Chemother Pharmacol. 1981;6:35-38.
47. Allegra CJ, Grem JL. Pharmacology of cancer chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 4th ed. Philadelphia, Pa: Lippincott-Williams & Wilkins; 1997.
48. Tidd DM, Paterson ARP. Distinction between inhibition of purine nucleotide synthesis and the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res. 1974; 34:733-737.
49. Ferenczi K, Burack L, Pope M, Krueger JG, Austin LM. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun. In press.
50. Ozawa M, Ferenczi K, Kikuchi T, et al. 312 nm UVB (narrow band) induces apoptosis of T cells within psoriatic lesions. J Exp Med. 1999;189:711-718.
51. Coven TR, Murphy FP, Gilleaudeau P, Cardinale I, Krueger JG. Trimethylpsoralen bath PUVA is a remittive treatment for psoriasis vulgaris; evidence that epidermal immunocytes are direct therapeutic targets. Arch Dermatol. 1998;134: 1263-1268.
52. Gottlieb SL, Hayes E, Gilleaudeau P, Cardinale I, Gottlieb AB, Krueger JG. Cellular actions of etretinate in psoriasis: enhanced epidermal differentiation and reduced cell-mediated inflammation are unexpected outcomes. J Cutan Pathol. 1996; 23:404-418.
53. Gottlieb AB, Krueger JG, Khandke L, et al. Cyclosporine A treatment decreases immune activation in psoriatic plaques without decreasing keratinocyte regenerative maturation (growth activation) [abstract]. J Invest Dermatol. 1991;96:570.
54. Silvis NG, Levine N. Pulse dosing of thioguanine in recalcitrant psoriasis. Arch Dermatol. 1999;135:433-437.